Eli Lilly to Expand Zepbound Availability with Higher Doses

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-06-19 19:50:17

Pharmaceutical heavyweight Eli Lilly (LLY) will introduce higher-dose variants of its blockbuster weight-loss drug Zepbound through its LillyDirect platform, with shipments commencing in August. The 12.5mg and 15mg doses will be priced at $499 monthly for self-paying patients, while healthcare providers gain prescribing access starting July 7.

The MOVE follows Lilly's 2023 rollout of lower-dose vials via LillyDirect, later discounted in February to compete with Novo Nordisk (NVO). Pricing remains contentious—while some patients pay as little as $25 monthly through insurance, the drug's $1,059 list price previously sparked accusations of price gouging from consumers and legislators alike.

By:

Log in to Reply

Visa Boosts USDC Adoption in CEMEA via Yellow Card Stablecoin Partnership

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.